CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,307,378 enrolled
Drug / intervention
Trumenba Vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05873751
NCT05873751N/ACompleted
CompareCT.gov

Effect of Trumenba on Gonococcal Infections in Adolescents and Young Adults in the United States: A Retrospective Cohort Study

Pfizer·observational·Posted May 24, 2023·Updated Apr 17, 2025

In Brief

An observational study evaluating Trumenba Vaccine and MenACWY Vaccine for Gonorrhea and 2 related conditions. Completed, enrolled 1,307,378 participants across 1 site.

Detailed Summary

Brief Summary: The main purpose of the study is to learn about how well Trumenba vaccine shot works against gonorrhea infection. This study looks at data records from a database in the United States. This study includes patient's data from the database who: * Are 15-30 years old. * Have received at least one dose of Trumenba and a MenACWY vaccine or who have received only MenACWY vaccine. This data has already been collected in the past and is being studied between April and June of 2023.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGonorrhea, Chlamydia, Meningococcal Vaccines
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedMay 24, 2023
Enrollment StartApr 24, 2023
Primary CompletionMar 31, 2024
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 3.1 years ago

Interventions

Trumenba Vaccinebiological

Trumenba vaccine given as standard of care

MenACWY Vaccinebiological

MenACWY Vaccine given as standard of care